A groundbreaking study has shed new light on the safety of a commonly prescribed medication for patients with chronic obstructive pulmonary disease (COPD). The findings could revolutionize how we treat this leading cause of preventable hospital admissions in Australia.
The study, led by researchers from The George Institute for Global Health, focused on the beta-blocker bisoprolol and its potential impact on respiratory health in COPD patients.
Here's the big revelation: Bisoprolol, a highly selective beta-1 blocker, has been found to be safe for COPD patients with moderate to severe symptoms. This is a game-changer, as it eases long-standing concerns that beta-blockers could worsen respiratory outcomes in this vulnerable population.
The multinational PACE trial, involving over 280 patients across Australia, India, New Zealand, and Sri Lanka, found no increase in exacerbations, decline in lung function, hospitalizations, or deaths when comparing bisoprolol to a placebo over a two-year period.
But here's where it gets controversial: While bisoprolol proved safe, it didn't offer much in terms of cardiovascular benefits either. This raises questions about the absolute risk of major cardiovascular events in COPD patients and the need to re-evaluate treatment strategies.
COPD is a complex disease, often accompanied by cardiovascular complications. Patients with COPD are at a high risk of dying from cardiovascular disease (CVD), almost as frequently as from their lung disease.
Treating CVD in COPD patients has been a challenge due to the belief that beta-blockers were contraindicated. However, large databases have suggested that this class of drugs could benefit COPD patients by reducing mortality and exacerbation rates.
The phase 3 study enrolled patients aged 40-85 with COPD. Participants were mostly male, with a mean age of 68, and had moderate to severe airflow limitation.
The results were clear: Bisoprolol did not improve overall cardiorespiratory outcomes compared to the placebo, with no significant differences in all-cause mortality, hospital admissions, major cardiac events, COPD exacerbations, lung function, symptoms, quality of life, or adverse events.
COPD exacerbations were the most common adverse event in both groups, and deaths occurred in a small percentage of participants, with none attributed to treatment.
Professor Christine Jenkins, the lead investigator, emphasized the importance of these findings, which align with a recent UK study published in JAMA. Both studies found no association between bisoprolol and increased respiratory or other adverse reactions in COPD patients.
Another key takeaway is the need for earlier diagnosis of COPD and assessment of cardiac risks in these patients.
"We don't know if cardiovascular medicines have the same effect on COPD patients as they do on the broader cardiovascular population," said Professor Jenkins.
Three high-quality studies, including the BLOCK COPD study published in the New England Journal, have shown no benefit with beta-blockers. This raises questions about how COPD patients respond to cardiovascular interventions and whether their lung disease influences the effectiveness of these treatments.
Different respiratory mechanics in COPD patients may also play a role.
"They tend to have a very rapid respiratory rate, which reduces their heart's filling time," explained Professor Jenkins.
This, along with other factors, may make COPD patients less responsive to cardiovascular interventions, medical treatments, and pharmacotherapy.
"We still have unanswered questions about managing cardiovascular disease in COPD," she added.
Interestingly, Professor Jenkins noted that major cardiovascular events like myocardial infarction, heart failure, and arrhythmia are more common in patients with moderate COPD than severe COPD.
"Earlier recognition of COPD and potential comorbid cardiac disease is crucial for GPs," she emphasized.
"The opportunity to take preventative steps in moderate COPD, such as stopping smoking, promoting exercise, reducing weight, controlling diabetes, and managing COPD optimally, can significantly impact life expectancy and reduce cardiac risks."
These findings, published in The Lancet Respiratory Medicine in January 2026, provide valuable insights into the safe use of bisoprolol in COPD patients. However, they also highlight the need for further research to optimize the management of cardiovascular disease in this complex patient population.
What are your thoughts on these findings? Do you think they will impact clinical practice? Share your insights and let's spark a discussion on this important topic!
